1. Home
  2. ACVA vs PHAR Comparison

ACVA vs PHAR Comparison

Compare ACVA & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACV Auctions Inc.

ACVA

ACV Auctions Inc.

HOLD

Current Price

$6.99

Market Cap

1.1B

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$14.30

Market Cap

885.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACVA
PHAR
Founded
2014
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
885.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
ACVA
PHAR
Price
$6.99
$14.30
Analyst Decision
Buy
Strong Buy
Analyst Count
12
3
Target Price
$11.32
$38.33
AVG Volume (30 Days)
2.8M
4.2K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
18.75
N/A
EPS
N/A
N/A
Revenue
$759,606,000.00
N/A
Revenue This Year
$14.01
$10.04
Revenue Next Year
$12.62
$2.51
P/E Ratio
N/A
$3,041.22
Revenue Growth
19.22
N/A
52 Week Low
$4.07
$9.54
52 Week High
$16.46
$21.34

Technical Indicators

Market Signals
Indicator
ACVA
PHAR
Relative Strength Index (RSI) 58.54 58.71
Support Level $6.18 $12.98
Resistance Level $8.37 $14.81
Average True Range (ATR) 0.33 0.41
MACD 0.04 0.20
Stochastic Oscillator 61.95 67.94

Price Performance

Historical Comparison
ACVA
PHAR

About ACVA ACV Auctions Inc.

ACV Auctions Inc operates a mobile platform for wholesale car auctions. It provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers. Additionally, the company's marketplace platform is supported by remarketing centers in various locations throughout the United States.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: